Doxycycline

Overview

Doxycycline, sold under the brand names Vibramycin and Doryx, among others, is a broad-spectrum antibiotic of the tetracycline class used in the treatment of infections caused by bacteria and certain parasites. It is used to treat bacterial pneumonia, acne, chlamydia infections, Lyme disease, cholera, typhus, and syphilis, and is sometimes used to prevent malaria. Doxycycline may be taken by mouth or intravenously.[1][2][3] WP

Common side effects include diarrhea, nausea, vomiting, abdominal pain, and an increased risk of sunburn. Use during pregnancy is not recommended. Doxycycline can be used in children of all ages, including for Lyme disease and rickettsial infections. Like other agents of the tetracycline class, it slows or kills bacteria by inhibiting protein production. It kills Plasmodium—microorganisms associated with malaria—by targeting a plastid organelle, the apicoplast.[1][4–8] WP

Doxycycline post-exposure prophylaxis (doxyPEP) is also used to prevent sexually transmitted infections, particularly when skin or fluid contact has occurred, such as if protection was not used in men who have sex with men, and is supported by CDC guidelines.[9][10] WP

Doxycycline was patented in 1957 and came into commercial use in 1967. It is on the World Health Organization's List of Essential Medicines. Doxycycline is available as a generic medicine. In 2023, it was the 77th most commonly prescribed medication in the United States, with more than 8 million prescriptions.[1][11–16] WP

Uses, dosage and effects

Medical uses

Like all tetracycline antibiotics, doxycycline is indicated for susceptible Gram-positive and Gram-negative bacterial infections, including respiratory tract infections and urinary tract infections. Beyond these general tetracycline indications, doxycycline is frequently used to treat Lyme disease, chronic prostatitis, sinusitis, pelvic inflammatory disease, severe acne, rosacea, and rickettsial infections. The efficacy of oral doxycycline for treating papulopustular rosacea and adult acne is not solely based on its antibiotic properties, but also on its anti-inflammatory and anti-angiogenic properties.[17–23] WP

General indications

Doxycycline is a broad-spectrum antibiotic that is employed in the treatment of numerous bacterial infections. The drug is effective against bacteria such as Moraxella catarrhalis (a cause of respiratory tract infections), Brucella melitensis (a cause of brucellosis), Chlamydia pneumoniae (a cause of atypical pneumonia), and Mycoplasma pneumoniae (a cause of pneumonia). Additionally, doxycycline is used in the prevention and treatment of serious conditions like anthrax, leptospirosis, bubonic plague, and Lyme disease. However, some bacteria have developed resistance to doxycycline, including Haemophilus species, Mycoplasma hominis, and Pseudomonas aeruginosa.[24][25] WP

Specifically, doxycycline is indicated for treatment of the following diseases:[26][27] WP

• Rocky Mountain spotted fever, typhus fever and the typhus group, scrub typhus, Q fever, rickettsialpox, and tick fevers caused by Rickettsia,[5][28–31] WP
• respiratory tract infections caused by Mycoplasma pneumoniae,[32] WP
• Lymphogranuloma venereum, trachoma, inclusion conjunctivitis, and uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis,[26][27] WP
• psittacosis,[26][27] WP
• non-gonococcal urethritis caused by Ureaplasma urealyticum,[26][27] WP
• relapsing fever due to Borrelia recurrentis,[26][27] WP
• chancroid caused by Haemophilus ducreyi,[26][27] WP
• plague due to Yersinia pestis,[26][27] WP
• tularemia,[26][27] WP
• cholera,[26][27] WP
• campylobacter fetus infections,[26][27] WP
• brucellosis caused by Brucella species (in conjunction with streptomycin),[26][27] WP
• bartonellosis,[26][27] WP
• granuloma inguinale (Klebsiella species),[26][27] WP
• Lyme disease (Borrelia species).[33] WP
• Leptospirosis[34][35][36] WP

Indications for gram-negative bacteria

When bacteriologic susceptibility testing (laboratory tests confirming the bacteria are sensitive to the drug) indicates appropriate susceptibility, doxycycline may be used to treat these infections caused by Gram-negative bacteria:[26][27] WP

• Escherichia coli infections,[26][27] WP
• Klebsiella aerogenes infections,[26][27] WP
• Shigella species infections,[26][27] WP
• Acinetobacter species infections,[26][27] WP
• respiratory tract infections caused by Haemophilus influenzae,[26][27] WP
• respiratory tract and urinary tract infections caused by Klebsiella species.[26][27] WP

Indications for gram-positive bacteria

Some Gram-positive bacteria have developed resistance to doxycycline. Tetracycline resistance rates vary by geographic region; for example, resistance in Streptococcus pyogenes ranges from about 1% in Sweden to over 80% in China, and a pooled global resistance rate of approximately 67% has been reported for Enterococcus faecalis. When bacteriologic susceptibility testing indicates appropriate susceptibility to the drug, doxycycline may be used to treat these infections caused by Gram-positive bacteria:[26][27] WP

• upper respiratory infections caused by Streptococcus pneumoniae,[26][27] WP
• skin and soft tissue infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) infections,[26][27] WP
• anthrax caused by Bacillus anthracis infection.[26][27] WP

Use as adjunctive therapy

Doxycycline is used as an adjunctive therapy for severe acne, acute intestinal amebiasis, and chancroid.[26][27][37][38] WP

Subantimicrobial-dose doxycycline (SDD) is widely used as an adjunctive treatment to scaling and root planing for periodontitis. SDD is also used to treat skin conditions such as acne and rosacea, including ocular rosacea. In ocular rosacea, treatment period is 2 to 3 months. After discontinuation of doxycycline, recurrences may occur within three months; therefore, many studies recommend either slow tapering or treatment with a lower dose over a longer period of time.[19][39–42] WP

As prophylaxis against sexually transmitted infections

Doxycycline is used as post-exposure prophylaxis (PEP) to prevent certain sexually transmitted infections, known as doxycycline post-exposure prophylaxis (doxyPEP). A landmark randomized trial in San Francisco found that a single 200 mg dose of doxycycline taken within 72 hours after condomless sex reduced the overall incidence of bacterial STIs by approximately two-thirds among men who have sex with men (MSM) and transgender women, with reductions of 87–88% for chlamydia, 73–87% for syphilis, and 55% for gonorrhea. However, a separate trial found doxyPEP was not effective in cisgender women.[10][43] WP

In June 2024, the US Centers for Disease Control and Prevention (CDC) issued clinical guidelines recommending doxyPEP for MSM and transgender women with at least one bacterial STI in the prior 12 months. The Australasian Society for HIV Medicine issued a more cautious consensus statement recommending doxyPEP only for syphilis prevention in MSM, citing concerns that the risk of increasing antimicrobial resistance, especially in Neisseria gonorrhoeae, outweighed the benefits for other STIs. Use of doxyPEP has been associated with tetracycline resistance in N. gonorrhoeae.[9][44][45] WP

Use in combination

The first-line treatment for brucellosis is a combination of doxycycline and streptomycin. The second-line treatment is a combination of doxycycline and rifampicin (rifampin).[46] WP

Antimalarial

Doxycycline is active against the erythrocytic stages of Plasmodium falciparum, a protozoan parasite that causes malaria, but it is not active against the gametocytes of P. falciparum. As such, doxycycline is used to prevent malaria, but not recommended alone for initial treatment of malaria, even when the parasite is doxycycline-sensitive, because the antimalarial effect of doxycycline is delayed by 48 to 96 hours owing to a "delayed death" mechanism in which parasites complete their current replication cycle before dying in the next cycle. For this reason, doxycycline prophylaxis must be continued for four weeks after leaving a malarious area, compared with only seven days for atovaquone/proguanil.[47][48][49] WP

Doxycycline blocks protein production in the apicoplast (an organelle) of P. falciparum. This disrupts the parasite's ability to produce fatty acids, which are essential for its growth, and impairs the production of heme, a cofactor. These effects occur late in the parasite's life cycle during the blood stage (the erythrocytic cycle, when the parasite replicates inside human red blood cells). By blocking important processes in the parasite, doxycycline both inhibits the growth and prevents the replication of P. falciparum. Doxycycline does not directly kill living P. falciparum, but creates conditions that prevent their growth and replication.[19][50] WP

The World Health Organization (WHO) guidelines state that the combination of doxycycline with either artesunate or quinine may be used for the treatment of uncomplicated malaria due to P. falciparum or following intravenous treatment of severe malaria.[51] WP

Deworming

Doxycycline can be used against parasitic nematodes (worms) that cause filariasis. It kills symbiotic bacteria of the genus Wolbachia in the reproductive tracts of the nematodes, making the nematodes sterile (unable to reproduce). This reduces transmission of diseases such as onchocerciasis and elephantiasis. A randomized controlled trial showed that an eight-week course of doxycycline almost eliminates the release of microfilariae (larval offspring of the nematodes).[52][53][54] WP

Spectrum of susceptibility

Doxycycline has been used successfully to treat sexually transmitted, respiratory, and eye infections. Representative pathogenic genera include Chlamydia, Streptococcus, Ureaplasma, Mycoplasma, and others. The minimum inhibitory concentration for a few medically significant microorganisms are:[55] WP

• Chlamydia psittaci: 0.03 μg/mL[55] WP
• Mycoplasma pneumoniae: 0.016–2 μg/mL[55] WP
• Streptococcus pneumoniae: 0.06–32 μg/mL[55] WP

Sclerotherapy

Doxycycline is also used for sclerotherapy in venous and lymphatic malformations, as well as post-operative lymphoceles (collections of lymph fluid outside of lymphatic vessels).[56] WP

Off-label use

Doxycycline is used off-label in the treatment of transthyretin amyloidosis (ATTR). In combination with tauroursodeoxycholic acid, doxycycline has been shown to disrupt transthyretin (TTR) fibrils in existing amyloid deposits of ATTR patients, and is being investigated as a potential treatment option for this condition.[57] WP

Routes of administration

Doxycycline can be administered orally or intravenously.[1] WP

The combination of doxycycline with dairy, antacids, calcium supplements, iron products, laxatives containing magnesium, or bile acid sequestrants may decrease absorption of doxycycline, though these interactions are not inherently dangerous.[58][59] WP

Doxycycline has a high oral bioavailability, as it is almost completely absorbed in the stomach and proximal small intestine. Unlike older tetracyclines, whose absorption is substantially reduced by food, doxycycline absorption is only modestly affected: co-administration of dairy products reduces the serum concentration of doxycycline by about 20%, compared with a 50% reduction for tetracycline. Doxycycline absorption is inhibited by cations with a 2+ or 3+ charge (divalent and trivalent cations), such as iron, bismuth, aluminum, calcium, and magnesium. Doxycycline forms unstable complexes with these metal ions in the acidic environment of the stomach; most of these complexes dissociate in the small intestine, allowing the drug to be absorbed. However, some doxycycline remains complexed with metal ions in the duodenum, resulting in a slight decrease in absorption.[19] WP

Dosing

Although doxycycline is approved to treat Lyme disease, the optimal dosing and duration of treatment for this condition is a topic of ongoing research. it can be used in adults and children. For treatment or prophylaxis of Lyme disease in children, it can be used for a duration of up to 21 days in children of any age. Doxycycline is specifically indicated to treat Lyme disease for patients presenting with erythema migrans. As for the optimal duration of treatment of this disease, guidelines vary, with some recommending a 10-day course of doxycycline, while others suggest a 14-day course; still, recent data suggest that even a 7-day course of doxycycline can be effective. Compared to other drugs, there are no significant differences in treatment response across antibiotic agents, doses, or durations when comparing 14 days versus 21 days; as such, the optimal duration of treatment of Lyme disease remains uncertain, as prolonged antibiotic courses have drawbacks, including diminishing returns in terms of patient outcomes, heightened risks of adverse events, superinfections, increased healthcare costs, and the potential for development of antibiotic resistance. Therefore, the consensus remains to treat patients with the shortest effective duration of antibiotics, as is the case with doxycycline for Lyme disease as well.[4][33][60] WP

Risks and side effects

Penicillin contraindication

When penicillin is contraindicated, doxycycline can be used to treat:[26][27] WP

• syphilis caused by Treponema pallidum,[26][27] WP
• yaws caused by Treponema pertenue,[26][27] WP
• listeriosis due to Listeria monocytogenes,[26][27] WP
• Vincent's infection caused by Fusobacterium fusiforme,[26][27] WP
• actinomycosis caused by Actinomyces israelii,[26][27] WP
• infections caused by Clostridium species.[26][27] WP

Contraindications

Doxycycline is contraindicated (should not be used) in patients with severe liver disease or those taking isotretinoin or other retinoids, as both tetracyclines and retinoids can cause intracranial hypertension (increased pressure around the brain) in rare cases.[58] WP

Pregnancy and lactation

Doxycycline is categorized by the FDA as a class D drug in pregnancy, meaning there is evidence of risk to the fetus but the benefits may outweigh the risks in certain situations. Doxycycline crosses into breast milk and is therefore a concern during breastfeeding. Other tetracycline antibiotics are contraindicated in pregnancy and up to eight years of age, due to the potential for disrupting bone and tooth development. The FDA includes a class warning for all tetracyclines about staining of teeth (typically yellow to brown discoloration) and decreased development of dental enamel in children exposed to tetracyclines in utero, during breastfeeding, or during early childhood (under eight years of age). However, the FDA has acknowledged that the actual risk of dental staining of primary teeth is undetermined for doxycycline specifically. The best available evidence indicates that doxycycline has little or no effect on hypoplasia (underdevelopment) of dental enamel or on staining of primary teeth (baby teeth). The US Centers for Disease Control and Prevention (CDC) recommends the use of doxycycline for treatment of Q fever and tick-borne rickettsial diseases in children of all ages, and some researchers advocate for its use in children with malaria as well.[61–64] WP

Adverse effects

Adverse effects of doxycycline are similar to those of other members of the tetracycline antibiotic group. Doxycycline can cause gastrointestinal upset. Oral doxycycline can cause pill esophagitis, particularly when it is swallowed without adequate fluid, or by persons with difficulty swallowing or reduced gastrointestinal motility. Doxycycline is less likely than other antibiotic drugs to cause Clostridioides difficile colitis.[65–68] WP

An erythematous (red) rash in sun-exposed parts of the body has been reported to occur in 7.3–21.2% of persons taking doxycycline as prophylaxis against malaria. The rash resolves upon discontinuation of the drug. One study examined the tolerability of various malaria prophylactic regimens and found doxycycline did not cause a significantly higher percentage of skin events (such as rash, itching, or photosensitivity) when compared with other antimalarials.[69] WP

Unlike some other members of the tetracycline group, doxycycline may be used in those with renal impairment, because it is primarily excreted via the feces rather than the kidneys, and does not accumulate to toxic levels when kidney function is reduced.[70] WP

Doxycycline use has been associated with increased risk of inflammatory bowel disease. In one large retrospective study, patients who were prescribed doxycycline for their acne had a 2.25-fold greater risk of developing Crohn's disease.[71][72] WP

Interactions

Interactions

Previously, doxycycline was believed to impair the effectiveness of many types of hormonal contraception due to induction of CYP450 enzymes (a family of liver enzymes that break down drugs, potentially accelerating the metabolism of hormonal contraceptives). Research has shown no significant loss of effectiveness in oral contraceptives while using most tetracycline antibiotics (including doxycycline), although many physicians still recommend the use of barrier contraception for people taking the drug to prevent unwanted pregnancy.[70][73][74] WP

Pharmacology

Pharmacodynamics

Doxycycline, like other tetracycline antibiotics, is bacteriostatic. The drug works by preventing bacteria from reproducing, inhibiting protein synthesis.[75] WP

Doxycycline is highly lipophilic, so it can easily enter cells, meaning the drug is readily absorbed and has a large volume of distribution (it distributes widely throughout body tissues rather than remaining in the blood). The drug can also be re-absorbed in the renal tubules and gastrointestinal tract due to its high lipophilicity, giving it a long elimination half-life. In patients with kidney failure, doxycycline does not accumulate to toxic levels because the body compensates by increasing excretion through the feces. Doxycycline-metal ion complexes are unstable in acidic conditions, therefore more doxycycline enters the duodenum for absorption than older tetracycline compounds such as tetracycline and oxytetracycline. In addition, food has less effect on the absorption of doxycycline than on other tetracyclines, with doxycycline serum concentrations being reduced by about 20% by test meals compared with 50% for tetracycline.[66][76][77] WP

Mechanism of action

Doxycycline is a broad-spectrum bacteriostatic antibiotic. It inhibits the synthesis of bacterial proteins by binding to the 30S ribosomal subunit, which is only found in bacteria. This prevents the binding of transfer RNA to messenger RNA at the ribosomal subunit, meaning amino acids cannot be added to polypeptide chains and new proteins cannot be made. This stops bacterial growth, giving the immune system time to kill the bacteria.[65][76][78] WP

In rosacea treatment, doxycycline inhibits neutrophil chemotaxis and oxidative bursts (common mechanisms of inflammation and reactive oxygen species activity in rosacea), and it also suppresses matrix metalloproteases and kallikrein 5 which in turn reduce the expression of the human cathelicidin antimicrobial peptide (LL-37) and limit downstream inflammatory cascades.[23] WP

Absorption and excretion

Doxycycline is almost completely absorbed from the stomach and upper part of the small intestine (duodenum and jejunum). It reaches highest concentrations in the blood plasma after one to two hours and has a high plasma protein binding rate of about 80–90%. Doxycycline penetrates into almost all tissues and body fluids. High concentrations are found in the gallbladder, liver, kidneys, lungs, breast milk, bones, and genitals; low concentrations are found in saliva, aqueous humor, cerebrospinal fluid (CSF), and especially in inflamed meninges. By comparison, the tetracycline antibiotic minocycline penetrates significantly better into the CSF and meninges.[58][79][80] WP

Doxycycline metabolism (breakdown by the body) is negligible. The drug is actively excreted into the gut (in part via the gallbladder, in part directly from blood vessels), where some of it is inactivated by forming chelates. About 40% are eliminated via the kidneys, much less in people with end-stage kidney disease. The biological half-life is 18 to 22 hours (16 ± 6 hours according to another source) in healthy people, slightly longer in those with end-stage kidney disease, and significantly longer in those with liver disease.[58][79][80] WP

Research

Research reagent

Doxycycline and other members of the tetracycline class of antibiotics are often used as research reagents in in vitro and in vivo biomedical research experiments involving bacteria as well in experiments in eukaryotic cells and organisms with inducible protein expression systems using tetracycline-controlled transcriptional activation. The mechanism of action for the antibacterial effect of tetracyclines relies on disrupting protein translation in bacteria, thereby damaging the ability of microbes to grow and repair; however protein translation is also disrupted in eukaryotic mitochondria impairing metabolism and leading to effects that can confound experimental results. Doxycycline is also used in "tet-on" (gene expression activated by doxycycline) and "tet-off" (gene expression inactivated by doxycycline) tetracycline-controlled transcriptional activation to regulate transgene expression in organisms and cell cultures. Doxycycline is more stable than tetracycline for this purpose. At subantimicrobial doses, doxycycline is an inhibitor of matrix metalloproteases, and has been used in various experimental systems for this purpose, such as for recalcitrant recurrent corneal erosions.[23][81–84] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.⚠ A word may be missing here. It reads this way in the source too.

Medical conditions

Research areas on the application of doxycycline include the following medical conditions: WP

• macular degeneration;[85] WP
• rheumatoid arthritis instead of minocycline (both of which have demonstrated modest efficacy for this disease).[86] WP

Anti-inflammatory agent

Some studies show doxycycline as a potential agent to possess anti-inflammatory properties acting by inhibiting proinflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and matrix metalloproteinases (MMPs) while increasing the production of anti-inflammatory cytokines such as interleukin-10 (IL-10). Cytokines are small proteins that are secreted by immune cells and help regulate the immune response. Some studies suggest that doxycycline can suppress the activation of the nuclear factor-kappa B (NF-κB) pathway, which is responsible for upregulating several inflammatory mediators in various cells, including neurons; therefore, it is studied as a potential agent for treating neuroinflammation.[23][87][88][89] WP

A potential explanation of doxycycline's anti-inflammatory properties is its inhibition of matrix metalloproteinases (MMPs), which are a group of proteases known to regulate the turnover of extracellular matrix (ECM) and thus are suggested to be important in the process of several diseases associated with tissue remodeling and inflammation. Doxycycline has been shown to inhibit MMPs, including matrilysin (MMP7), by interacting with the structural zinc atom and/or calcium atoms within the structural metal center of the protein.[23][90–96] WP

Doxycycline also inhibits allikrein-related peptidase 5 (KLK5). The inhibition of MMPs and KLK5 enzymes subsequently suppresses the expression of LL-37, a cathelicidin antimicrobial peptide that, when overexpressed, can trigger inflammatory cascades. By inhibiting LL-37 expression, doxycycline helps to mitigate these downstream inflammatory cascades, thereby reducing inflammation and the symptoms of inflammatory conditions.[93] WP

Doxycycline is used to treat acne vulgaris and rosacea. However, there is no clear understanding of what contributes more: the bacteriostatic properties of doxycycline, which affect bacteria (such as Propionibacterium acnes) on the surface of sebaceous glands even in lower doses called "submicrobial" or "subantimicrobial", or whether doxycycline's anti-inflammatory effects, which reduce inflammation in acne vulgaris and rosacea, including ocular rosacea, contribute more to its therapeutic effectiveness against these skin conditions. Subantimicrobial-dose doxycycline (SDD) can still have a bacteriostatic effect, especially when taken for extended periods, such as several months in treating acne and rosacea. While the SDD is believed to have anti-inflammatory effects rather than solely antibacterial effects, SDD was proven to work by reducing inflammation associated with acne and rosacea. Still, the exact mechanisms have yet to be fully discovered. One probable mechanism is doxycycline's ability to decrease the amount of reactive oxygen species (ROS). Inflammation in rosacea may be associated with increased production of ROS by inflammatory cells; these ROS contribute toward exacerbating symptoms. Doxycycline may reduce ROS levels and induce antioxidant activity because it directly scavenges hydroxyl radicals and singlet oxygen, helping minimize tissue damage caused by highly oxidative and inflammatory conditions. Studies have shown that SDD can effectively improve acne and rosacea symptoms, probably without inducing antibiotic resistance. It is observed that doxycycline exerts its anti-inflammatory effects by inhibiting neutrophil chemotaxis and oxidative bursts, which are common mechanisms involved in inflammation and ROS activity in rosacea and acne.[19][23][42][97–109] WP

Doxycycline's dual benefits as an antibacterial and anti-inflammatory make it a helpful treatment option for diseases involving inflammation of the skin, such as rosacea and acne, and in conditions such as osteoarthritis or periodontitis. Nevertheless, current results are inconclusive, and evidence of doxycycline's anti-inflammatory properties needs to be improved, considering conflicting reports from animal models so far. Doxycycline has been studied in various immunological disorders, including rheumatoid arthritis, lupus, and periodontitis. In these conditions, doxycycline has been researched to determine anti-inflammatory and immunomodulatory effects that could be beneficial in treating these conditions. However, a solid conclusion still needs to be provided.[110–118] WP

Doxycycline is also studied for its neuroprotective properties which are associated with antioxidant, anti-apoptotic, and anti-inflammatory mechanisms. In this context, doxycycline is able to cross the blood–brain barrier. Several studies have shown that doxycycline inhibits dopaminergic neurodegeneration through the upregulation of axonal and synaptic proteins. Axonal degeneration and synaptic loss are key events at the early stages of neurodegeneration and precede neuronal death in neurodegenerative diseases, including Parkinson's disease (PD). Therefore, the regeneration of the axonal and synaptic network might be beneficial in PD. It has been demonstrated that doxycycline mimics nerve growth factor (NGF) signaling in PC12 cells. However, the involvement of this mechanism in the neuroprotective effect of doxycycline is unknown. Doxycycline is also studied in reverting inflammatory changes related to depression. While there is some research on the use of doxycycline for treating major depressive disorder, the results are mixed.[102][119–123] WP

After a large-scale trial showed no benefit of using doxycycline in treating COVID19, the UK's National Institute for Health and Care Excellence (NICE) updated its guidance to not recommend the medication for the treatment of COVID19. Doxycycline was expected to possess anti-inflammatory properties that could lessen the cytokine storm associated with a SARS-CoV-2 infection, but the trials did not demonstrate the expected benefit. Researchers also believed that doxycycline possesses anti-inflammatory and immunomodulatory effects that could reduce the production of cytokines in COVID-19, but these supposed effects failed to improve the outcome of COVID-19 treatment.[124–128] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

Wound healing

Research on novel drug formulations for the delivery of doxycycline in wound treatment is expanding, focusing on overcoming stability limitations for long-term storage and developing consumer-friendly, parenteral antibiotic delivery systems. The most common and practical form of doxycycline delivery is through wound dressings, which have evolved from mono- to three-layered systems to maximize healing effectiveness.[129] WP

Research directions on the use of doxycycline in wound healing include the continuous stabilization of doxycycline, scaling up technology and industrial production, and exploring non-contact wound treatment methods like sprays and aerosols for use in emergencies and when medical care is not readily accessible.[129] WP

History

History

After penicillin came into wide use for bacterial infections in World War II, many chemical companies moved into the field of discovering antibiotics by bioprospecting. American Cyanamid was one of these, and in the late 1940s chemists there discovered chlortetracycline, the first member of the tetracycline class of antibiotics. Shortly thereafter, scientists at Pfizer discovered oxytetracycline and it was brought to market. Both compounds, like penicillin, were natural products and it was commonly believed that nature had perfected them, and further chemical changes could only degrade their effectiveness. Scientists at Pfizer led by Lloyd Conover modified these compounds, which led to the invention of tetracycline itself, the first semi-synthetic antibiotic. Charlie Stephens' group at Pfizer worked on further analogs and created one with greatly improved stability and pharmacological efficacy: doxycycline. Doxycycline was clinically developed in the early 1960s and approved by the US Food and Drug Administration (FDA) in 1967.[6] WP

As its patent grew near to expiring in the early 1970s, the patent became the subject of lawsuit between Pfizer and International Rectifier that was not resolved until 1983; at the time it was the largest litigated patent case in US history. Instead of a cash payment for infringement, Pfizer took the veterinary and feed-additive businesses of International Rectifier's subsidiary, Rachelle Laboratories.[130][131] WP

In January 2013, the FDA reported shortages of some, but not all, forms of doxycycline "caused by increased demand and manufacturing issues". Companies involved included an unnamed major generics manufacturer that ceased production in February 2013, Teva (which ceased production in May 2013), Mylan, Actavis, and Hikma Pharmaceuticals. The shortage came at a particularly bad time, since there were also shortages of an alternative antibiotic, tetracycline, at the same time. The market price for doxycycline dramatically increased in the United States in 2013 and early 2014 (from $20 to over $1800 for a bottle of 500 tablets), before decreasing again.[132–140] WP

Legal status

Brand names

Doxycycline is available worldwide under many brand names.[141] WP

Generic availability

Doxycycline is available as a generic medicine.[1][14] WP

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Doxycycline calcium
2. Other Malaria
3. Journal / agency Choosing a Drug to Prevent Malaria. February 2023
4. Journal / agency Taylor-Salmon E, Shapiro ED. Tick-borne infections in children in North America. Curr Opin Pediatr. April 2024. doi:10.1097/MOP.0000000000001326 · PMID 38167816 · PMC10932821
5. Other Schutze GE, Regan J, Bradley J. Use doxycycline as first-line treatment for rickettsial diseases. 1 July 2010
6. Journal / agency Nelson ML, Levy SB. The history of the tetracyclines. Annals of the New York Academy of Sciences. December 2011. doi:10.1111/j.1749-6632.2011.06354.x · PMID 22191524
7. Journal / agency McFadden GI. Apicoplast. Current Biology. March 2014. doi:10.1016/j.cub.2014.01.024 · PMID 24698369
8. Other Schlagenhauf-Lawlor P. Travelers' Malaria. 2008
9. Journal / agency Bachmann LH, Barbee LA, Chan P, Reno H, Workowski KA, Hoover K, Mermin J, Mena L. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR Recommendations and Reports. June 2024. doi:10.15585/mmwr.rr7302a1 · PMID 38833414 · PMC11166373
10. Journal / agency Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, Malinski C, Perkins R, Nasser M, Lopez C, Vittinghoff E, Buchbinder SP, Scott H, Charlebois ED, Havlir DV, Soge OO, Celum C. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. New England Journal of Medicine. April 2023. doi:10.1056/NEJMoa2211934 · PMID 37018493 · PMC10140182
11. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
12. Other Corey EJ. Drug discovery practices, processes, and perspectives. 2013
13. Other World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). 2023
14. Other Hamilton RJ. Tarascon pharmacopoeia. 2011
15. Other Top 300 of 2023
16. Other Doxycycline Drug Usage Statistics, United States, 2014 - 2023
17. Journal / agency Sweet RL, Schachter J, Landers DV, Ohm-Smith M, Robbie MO. Treatment of hospitalized patients with acute pelvic inflammatory disease: comparison of cefotetan plus doxycycline and cefoxitin plus doxycycline. American Journal of Obstetrics and Gynecology. March 1988. doi:10.1016/S0002-9378(16)44537-0 · PMID 3162653
18. Journal / agency Gjønnaess H, Holten E. Doxycycline (Vibramycin) in pelvic inflammatory disease. Acta Obstetricia et Gynecologica Scandinavica. 1978. doi:10.3109/00016347809155893 · PMID 345730
19. Journal / agency Holmes NE, Charles PG. Safety and Efficacy Review of Doxycycline. Clinical Medicine. Therapeutics. 5 January 2009. doi:10.4137/CMT.S2035
20. Journal / agency Määttä M, Kari O, Tervahartiala T, Peltonen S, Kari M, Saari M, Sorsa T. Tear fluid levels of MMP-8 are elevated in ocular rosacea--treatment effect of oral doxycycline. Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie. August 2006. doi:10.1007/s00417-005-0212-3 · PMID 16411105
21. Journal / agency Quarterman MJ, Johnson DW, Abele DC, Lesher JL, Hull DS, Davis LS. Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Archives of Dermatology. January 1997. doi:10.1001/archderm.133.1.49 · PMID 9006372
22. Journal / agency Walker DH, Paddock CD, Dumler JS. Emerging and re-emerging tick-transmitted rickettsial and ehrlichial infections. The Medical Clinics of North America. November 2008. doi:10.1016/j.mcna.2008.06.002 · PMID 19061755
23. Journal / agency Lee JJ, Chien AL. Rosacea in Older Adults and Pharmacologic Treatments. Drugs Aging. May 2024. doi:10.1007/s40266-024-01115-y · PMID 38649625
24. Other Doxycycline spectrum of bacterial susceptibility and Resistance
25. Other Stoddard RA, Galloway RL, Guerra MA. Yellow Book. 10 July 2015
26. Journal / agency Doxycycline, ANDA no. 065055 Label. 14 December 2012
27. Journal / agency Doxycycline, ANDA no. 065454 Label. 16 July 2008
28. Journal / agency Gupta N, Boodman C, Jouego CG, Van Den Broucke S. Doxycycline vs azithromycin in patients with scrub typhus: a systematic review of literature and meta-analysis. BMC Infect Dis. December 2023. doi:10.1186/s12879-023-08893-7 · PMID 38110855 · PMC10726538
29. Journal / agency Anderson A, Bijlmer H, Fournier PE, Graves S, Hartzell J, Kersh GJ, Limonard G, Marrie TJ, Massung RF, McQuiston JH, Nicholson WL, Paddock CD, Sexton DJ. Diagnosis and management of Q fever, United States, 2013: recommendations from CDC and the Q Fever Working Group. MMWR. Recommendations and Reports. March 2013. PMID 23535757
30. Journal / agency Biggs HM, Behravesh CB, Bradley KK, Dahlgren FS, Drexler NA, Dumler JS, Folk SM, Kato CY, Lash RR, Levin ML, Massung RF, Nadelman RB, Nicholson WL, Paddock CD, Pritt BS, Traeger MS. Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis — United States. MMWR. Recommendations and Reports. 2016. doi:10.15585/mmwr.rr6502a1 · PMID 27172113
31. Other Spotted fever group rickettsial disease | DermNet. 26 October 2023
32. Journal / agency Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, Chiba N, Iwata S, Ubukata K. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clinical Infectious Diseases. December 2012. doi:10.1093/cid/cis784 · PMID 22972867
33. Journal / agency Lyme disease. Treatment. 21 December 2018
34. Journal / agency U.S. Centers for Disease Control and Prevention. CDC Yellow Book: Health Information for International Travel. 23 April 2025
35. Journal / agency Wang S, Dunn N. StatPearls. 10 September 2024. PMID 28722888
36. Journal / agency U.S. Centers for Disease Control and Prevention. LEPTOSPIROSIS Fact Sheet for Clinicians. 30 January 2018
37. Journal / agency Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. The Cochrane Database of Systematic Reviews. August 2012. doi:10.1002/14651858.CD002086.pub2 · PMID 22895927 · PMC7017847
38. Other Doxycycline Dosage Guide + Max Dose, Adjustments
39. Journal / agency Sgolastra F, Petrucci A, Gatto R, Giannoni M, Monaco A. Long-term efficacy of subantimicrobial-dose doxycycline as an adjunctive treatment to scaling and root planing: a systematic review and meta-analysis. Journal of Periodontology. November 2011. doi:10.1902/jop.2011.110026 · PMID 21417590
40. Journal / agency van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. The Cochrane Database of Systematic Reviews. April 2015. doi:10.1002/14651858.CD003262.pub5 · PMID 25919144 · PMC6481562
41. Journal / agency Cao H, Yang G, Wang Y, Liu JP, Smith CA, Luo H, Liu Y. Complementary therapies for acne vulgaris. The Cochrane Database of Systematic Reviews. January 2015. doi:10.1002/14651858.CD009436.pub2 · PMID 25597924 · PMC4486007
42. Journal / agency Avraham S, Khaslavsky S, Kashetsky N, Starkey SY, Zaslavsky K, Lam JM, Mukovozov I. Therapie der okulären Rosazea: Eine systematische Literatur-Übersicht: Treatment of ocular rosacea: a systematic review. J Dtsch Dermatol Ges. February 2024. doi:10.1111/ddg.15290_g · PMID 38361192
43. Journal / agency Stewart J. Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women. New England Journal of Medicine. 21 December 2023. doi:10.1056/NEJMoa2304007 · PMID 38118022 · PMC10805625
44. Journal / agency Cornelisse VJ, Riley B, Medland NA. Australian consensus statement on doxycycline post-exposure prophylaxis (doxy-PEP) for the prevention of syphilis, chlamydia and gonorrhoea among gay, bisexual and other men who have sex with men. Med J Aust. April 2024. doi:10.5694/mja2.52258 · PMID 38479437
45. Journal / agency Vanbaelen T, Manoharan-Basil SS, Kenyon C. 45 years of tetracycline post exposure prophylaxis for STIs and the risk of tetracycline resistance: a systematic review and meta-analysis. BMC Infect Dis. April 2024. doi:10.1186/s12879-024-09275-3 · PMID 38575877 · PMC10996150
46. Journal / agency Hashemi SH, Gachkar L, Keramat F, Mamani M, Hajilooi M, Janbakhsh A, Majzoobi MM, Mahjub H. Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. International Journal of Infectious Diseases. April 2012. doi:10.1016/j.ijid.2011.12.003 · PMID 22296864
47. Journal / agency Doryx- doxycycline hyclate tablet, delayed release. 23 October 2020
48. Journal / agency Malaria - Chapter 3 - 2018 Yellow Book | Travelers' Health | CDC
49. Journal / agency Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrobial Agents and Chemotherapy. September 2006. doi:10.1128/AAC.00394-06 · PMID 16940111 · PMC1563505
50. Journal / agency Gaillard T, Madamet M, Pradines B. Tetracyclines in malaria. Malar J. November 2015. doi:10.1186/s12936-015-0980-0 · PMID 26555664 · PMC4641395
51. Other Guidelines for the treatment of malaria. 2015
52. Journal / agency Portela CS, Mendes de Araújo CP, Moura Sousa P, Gomes Simão CL, Silva de Oliveira JC, Crainey JL. Filarial disease in the Brazilian Amazon and emerging opportunities for treatment and control. Current Research in Parasitology & Vector-borne Diseases. 2024. doi:10.1016/j.crpvbd.2023.100168 · PMID 38283060 · PMC10821485
53. Journal / agency Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, Pfarr KM, Adjei O, Büttner DW. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Medical Microbiology and Immunology. November 2003. doi:10.1007/s00430-002-0174-6 · PMID 12684759
54. Journal / agency Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet. 2005. doi:10.1016/S0140-6736(05)66591-9 · PMID 15964448
55. Other Doxycycline hyclate Susceptibility and Minimum Inhibitory Concentration (MIC) Data
56. Other Kaufman JA, Lee MJ. Vascular and interventional radiology. 22 June 2013
57. Journal / agency Muller M, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?. European Journal of Heart Failure. 7 January 2020. doi:10.1002/ejhf.1695 · PMID 31912620
58. Other Austria-Codex. 2020
59. Journal / agency PubMed Health. Doxycycline (By mouth). 1 July 2016
60. Journal / agency Roca Mora MM, Cunha LM, Godoi A, Donadon I, Clemente M, Marcolin P, Valenzuela SA, Wormser GP. Shorter versus longer duration of antimicrobial therapy for early Lyme disease: A systematic review and meta-analysis. Diagn Microbiol Infect Dis. June 2024. doi:10.1016/j.diagmicrobio.2024.116215 · PMID 38493509
61. Journal / agency Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. Paediatric Drugs. 2002. doi:10.2165/00128072-200204120-00006 · PMID 12431134
62. Journal / agency Mylonas I. Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration. Archives of Gynecology and Obstetrics. January 2011. doi:10.1007/s00404-010-1646-3 · PMID 20814687
63. Journal / agency Bioterrorism and Drug Preparedness - Doxycycline Use by Pregnant and Lactating Women. FDA. 3 November 2018
64. Journal / agency Gaillard T, Briolant S, Madamet M, Pradines B. The end of a dogma: the safety of doxycycline use in young children for malaria treatment. Malaria Journal. April 2017. doi:10.1186/s12936-017-1797-9 · PMID 28407772 · PMC5390373
65. Other Hitchings A, Lonsdale D, Burrage D, Baker E. Top 100 drugs: clinical pharmacology and practical prescribing. 2015
66. Journal / agency Riond JL, Riviere JE. Pharmacology and toxicology of doxycycline. Veterinary and Human Toxicology. October 1988. PMID 3055652
67. Journal / agency Affolter K, Samowitz W, Boynton K, Kelly ED. Doxycycline-induced gastrointestinal injury. Human Pathology. August 2017. doi:10.1016/j.humpath.2017.02.011 · PMID 28286288
68. Journal / agency Hung YP, Lee JC, Lin HJ, Liu HC, Wu YH, Tsai PJ, Ko WC. Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection. Antibiotics. June 2015. doi:10.3390/antibiotics4020216 · PMID 27025622 · PMC4790331
69. Journal / agency Tan KR, Magill AJ, Parise ME, Arguin PM. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. The American Journal of Tropical Medicine and Hygiene. April 2011. doi:10.4269/ajtmh.2011.10-0285 · PMID 21460003 · PMC3062442
70. Journal / agency Dréno B, Bettoli V, Ochsendorf F, Layton A, Mobacken H, Degreef H. European recommendations on the use of oral antibiotics for acne. European Journal of Dermatology. November–December 2004. PMID 15564203
71. Journal / agency Lee TW, Russell L, Deng M, Gibson PR. Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad. Internal Medicine Journal. August 2013. doi:10.1111/imj.12179 · PMID 23656210
72. Journal / agency Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. The American Journal of Gastroenterology. December 2010. doi:10.1038/ajg.2010.303 · PMID 20700115
73. Journal / agency Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. Journal of the American Academy of Dermatology. June 2002. doi:10.1067/mjd.2002.120448 · PMID 12063491
74. Journal / agency DeRossi SS, Hersh EV. Antibiotics and oral contraceptives. Dental Clinics of North America. October 2002. doi:10.1016/S0011-8532(02)00017-4 · PMID 12436822
75. Other Flower R, Rang HP, Dale MM, Ritter JM, Henderson G. Rang & Dale's Pharmacology. 2012
76. Journal / agency Maaland MG, Papich MG, Turnidge J, Guardabassi L. Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline. Journal of Clinical Microbiology. November 2013. doi:10.1128/JCM.01498-13 · PMID 23966509 · PMC3889732
77. Journal / agency Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. The Journal of Antimicrobial Chemotherapy. August 2006. doi:10.1093/jac/dkl224 · PMID 16816396
78. Harm reduction site Doxycycline
79. Other Arzneistoff-Profile. 2010
80. Other Doxycycline. Accessed 5 August 2020 drugs.com PPA doxycycline
81. Journal / agency Moullan N, Mouchiroud L, Wang X, Ryu D, Williams EG, Mottis A, Jovaisaite V, Frochaux MV, Quiros PM, Deplancke B, Houtkooper RH, Auwerx J. Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research. Cell Reports. March 2015. doi:10.1016/j.celrep.2015.02.034 · PMID 25772356 · PMC4565776
82. Journal / agency Chatzispyrou IA, Held NM, Mouchiroud L, Auwerx J, Houtkooper RH. Tetracycline antibiotics impair mitochondrial function and its experimental use confounds research. Cancer Research. November 2015. doi:10.1158/0008-5472.CAN-15-1626 · PMID 26475870 · PMC4631686
83. Journal / agency Gossen M, Freundlieb S, Bender G, Müller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. June 1995. doi:10.1126/science.7792603 · PMID 7792603
84. Journal / agency Dursun D, Kim MC, Solomon A, Pflugfelder SC. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. American Journal of Ophthalmology. July 2001. doi:10.1016/S0002-9394(01)00913-8 · PMID 11438047
85. Journal / agency Leung E, Landa G. Update on current and future novel therapies for dry age-related macular degeneration. Expert Review of Clinical Pharmacology. September 2013. doi:10.1586/17512433.2013.829645 · PMID 23971874
86. Journal / agency Greenwald RA. The road forward: the scientific basis for tetracycline treatment of arthritic disorders. Pharmacological Research. December 2011. doi:10.1016/j.phrs.2011.06.010 · PMID 21723947
87. Journal / agency Singh S, Khanna D, Kalra S. Minocycline and Doxycycline: More Than Antibiotics. Curr Mol Pharmacol. 2021. doi:10.2174/1874467214666210210122628 · PMID 33568043
88. Journal / agency Henehan M, Montuno M, De Benedetto A. Doxycycline as an anti-inflammatory agent: updates in dermatology. Journal of the European Academy of Dermatology and Venereology. November 2017. doi:10.1111/jdv.14345 · PMID 28516469
89. Journal / agency Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs of Today. January 2007. doi:10.1358/dot.2007.43.1.1025697 · PMID 17315050
90. Journal / agency Lagente V, Victoni T, Boichot E. Proteases and Their Receptors in Inflammation. 2011. doi:10.1007/978-3-0348-0157-7_5
91. Journal / agency Wang S, Liu C, Liu X, He Y, Shen D, Luo Q, Dong Y, Dong H, Pang Z. Effects of matrix metalloproteinase inhibitor doxycycline and CD147 antagonist peptide-9 on gallbladder carcinoma cell lines. Tumour Biol. October 2017. doi:10.1177/1010428317718192 · PMID 29034777
92. Journal / agency Jung JJ, Razavian M, Kim HY, Ye Y, Golestani R, Toczek J, Zhang J, Sadeghi MM. Matrix metalloproteinase inhibitor, doxycycline and progression of calcific aortic valve disease in hyperlipidemic mice. Sci Rep. September 2016. doi:10.1038/srep32659 · PMID 27619752 · PMC5020643
93. Journal / agency Wehrli JM, Xia Y, Offenhammer B, Kleim B, Müller D, Bach DR. Effect of the Matrix Metalloproteinase Inhibitor Doxycycline on Human Trace Fear Memory. eNeuro. February 2023. doi:10.1523/ENEURO.0243-22.2023 · PMID 36759188 · PMC9961363
94. Journal / agency Liu J, Xiong W, Baca-Regen L, Nagase H, Baxter BT. Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg. December 2003. doi:10.1016/s0741-5214(03)01022-x · PMID 14681644
95. Journal / agency García RA, Pantazatos DP, Gessner CR, Go KV, Woods VL, Villarreal FJ. Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry. Mol Pharmacol. April 2005. doi:10.1124/mol.104.006346 · PMID 15665254
96. Journal / agency Liu J, Khalil RA. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. Prog Mol Biol Transl Sci. 2017. doi:10.1016/bs.pmbts.2017.04.003 · PMID 28662828 · PMC5548434
97. Journal / agency Eichenfield DZ, Sprague J, Eichenfield LF. Management of Acne Vulgaris: A Review. JAMA. November 2021. doi:10.1001/jama.2021.17633 · PMID 34812859
98. Journal / agency Baldwin H. Oral Antibiotic Treatment Options for Acne Vulgaris. J Clin Aesthet Dermatol. September 2020. PMID 33133338 · PMC7577330
99. Journal / agency Parish LC, Parish JL, Routh HB, Witkowski JA. The treatment of acne vulgaris with low dosage doxycycline. Acta Dermatovenerol Croat. 2005. PMID 16146617
100. Journal / agency Stein Gold LF. Acne: What's New. Semin Cutan Med Surg. June 2016. doi:10.12788/j.sder.2016.036 · PMID 27538054
101. Journal / agency Kontochristopoulos G, Tsiogka A, Agiasofitou E, Kapsiocha A, Soulaidopoulos S, Liakou AI, Gregoriou S, Rigopoulos D. Efficacy of Subantimicrobial, Modified-Release Doxycycline Compared to Regular-Release Doxycycline for the Treatment of Hidradenitis Suppurativa. Skin Appendage Disord. November 2022. doi:10.1159/000524762 · PMID 36407641 · PMC9672876
102. Journal / agency Mello BSF, Chaves Filho AJM, Custódio CS, Rodrigues PA, Carletti JV, Vasconcelos SMM, Sousa FCF, Sanders LLO, Macedo DS. Doxycycline at subantimicrobial dose combined with escitalopram reverses depressive-like behavior and neuroinflammatory hippocampal alterations in the lipopolysaccharide model of depression. J Affect Disord. September 2021. doi:10.1016/j.jad.2021.05.083 · PMID 34161892
103. Journal / agency Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003. doi:10.1111/j.1540-9740.2003.03014.x · PMID 14673277
104. Journal / agency Navarro-Triviño FJ, Pérez-López I, Ruiz-Villaverde R. Doxycycline, an Antibiotic or an Anti-Inflammatory Agent? The Most Common Uses in Dermatology. Actas Dermosifiliogr (Engl Ed). September 2020. doi:10.1016/j.ad.2019.12.006 · PMID 32401726
105. Journal / agency Zolotarev O, Khakimova A, Rahim F, Senel E, Zatsman I, Gu D. Scientometric analysis of trends in global research on acne treatment. Int J Womens Dermatol. October 2023. doi:10.1097/JW9.0000000000000082 · PMID 37521754 · PMC10378739
106. Journal / agency Shields A, Barbieri JS. From Breakouts to Bargains: Strategies for Patient-Centered, Cost-effective Acne Care. Cutis. August 2023. doi:10.12788/cutis.0844 · PMID 37820334 · PMC10951614
107. Journal / agency Akamatsu H, Asada M, Komura J, Asada Y, Niwa Y. Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline. Acta Derm Venereol. 1992. doi:10.2340/0001555572178179 · PMID 1357852
108. Journal / agency Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. May 2016. doi:10.1016/j.jaad.2015.12.037 · PMID 26897386
109. Journal / agency Wise RD. Submicrobial doxycycline and rosacea. Compr Ther. 2007. doi:10.1007/s12019-007-8003-x · PMID 18004018
110. Journal / agency Ahuja TS. Doxycycline decreases proteinuria in glomerulonephritis. Am J Kidney Dis. August 2003. doi:10.1016/s0272-6386(03)00662-0 · PMID 12900822
111. Journal / agency Patel A, Khande H, Periasamy H, Mokale S. Immunomodulatory Effect of Doxycycline Ameliorates Systemic and Pulmonary Inflammation in a Murine Polymicrobial Sepsis Model. Inflammation. June 2020. doi:10.1007/s10753-020-01188-y · PMID 31955291 · PMC7224120
112. Journal / agency Martin V, Bettencourt AF, Santos C, Fernandes MH, Gomes PS. Unveiling the Osteogenic Potential of Tetracyclines: A Comparative Study in Human Mesenchymal Stem Cells. Cells. September 2023. doi:10.3390/cells12182244 · PMID 37759467 · PMC10526833
113. Journal / agency Waitayangkoon P, Moon SJ, Tirupur Ponnusamy JJ, Zeng L, Driban J, McAlindon T. Long-Term Safety Profiles Macrolides and Tetracyclines: A Systematic Review and Meta-analysis. J Clin Pharmacol. September 2023. doi:10.1002/jcph.2358 · PMID 37751595 · PMC11949418
114. Journal / agency Orylska-Ratynska M, Placek W, Owczarczyk-Saczonek A. Tetracyclines-An Important Therapeutic Tool for Dermatologists. Int J Environ Res Public Health. June 2022. doi:10.3390/ijerph19127246 · PMID 35742496 · PMC9224192
115. Journal / agency Santos M, Gonçalves-Santos E, Gonçalves R, Santos E, Campos C, Bastos D, Marques M, Souza R, Novaes R. Doxycycline aggravates granulomatous inflammation and lung microstructural remodeling induced by Schistosoma mansoni infection. Int Immunopharmacol. May 2021. doi:10.1016/j.intimp.2021.107462 · PMID 33611055
116. Journal / agency Florou DT, Mavropoulos A, Dardiotis E, Tsimourtou V, Siokas V, Aloizou AM, Liaskos C, Tsigalou C, Katsiari C, Sakkas LI, Hadjigeorgiou G, Bogdanos DP. Tetracyclines Diminish In Vitro IFN-γ and IL-17-Producing Adaptive and Innate Immune Cells in Multiple Sclerosis. Front Immunol. 2021. doi:10.3389/fimmu.2021.739186 · PMID 34899697 · PMC8662812
117. Journal / agency Garrido-Mesa J, Adams K, Galvez J, Garrido-Mesa N. Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications. Expert Opin Investig Drugs. May 2022. doi:10.1080/13543784.2022.2054325 · PMID 35294307 · PMC9115781
118. Journal / agency de Witte LD, Munk Laursen T, Corcoran CM, Kahn RS, Birnbaum R, Munk-Olsen T, Bergink V. A Sex-Dependent Association Between Doxycycline Use and Development of Schizophrenia. Schizophr Bull. July 2023. doi:10.1093/schbul/sbad008 · PMID 36869773 · PMC10318877
119. Journal / agency Santa-Cecília FV, Leite CA, Del-Bel E, Raisman-Vozari R. The Neuroprotective Effect of Doxycycline on Neurodegenerative Diseases. Neurotox Res. May 2019. doi:10.1007/s12640-019-00015-z · PMID 30798507
120. Journal / agency Paldino E, Balducci C, La Vitola P, Artioli L, D'Angelo V, Giampà C, Artuso V, Forloni G, Fusco FR. Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease. Mol Neurobiol. April 2020. doi:10.1007/s12035-019-01847-8 · PMID 31879858 · PMC7118056
121. Journal / agency do Amaral L, Dos Santos NAG, Sisti FM, Del Bel E, Dos Santos AC. Doxycycline inhibits dopaminergic neurodegeneration through upregulation of axonal and synaptic proteins. Naunyn-Schmiedeberg's Arch Pharmacol. August 2023. doi:10.1007/s00210-023-02435-3 · PMID 36843128
122. Journal / agency Lee JW, Lee H, Kang HY. Association between depression and antibiotic use: analysis of population-based National Health Insurance claims data. BMC Psychiatry. October 2021. doi:10.1186/s12888-021-03550-2 · PMID 34711196 · PMC8554858
123. Journal / agency Leyder E, Suresh P, Jun R, Overbey K, Banerjee T, Melnikova T, Savonenko A. Depression-related phenotypes at early stages of Aβ and tau accumulation in inducible Alzheimer's disease mouse model: Task-oriented and concept-driven interpretations. Behav Brain Res. February 2023. doi:10.1016/j.bbr.2022.114187 · PMID 36343696
124. Journal / agency Platform trial rules out treatments for COVID-19. NIHR Evidence. 31 May 2022. doi:10.3310/nihrevidence_50873
125. Journal / agency Butler CC, Yu LM, Dorward J, Gbinigie O, Hayward G, Saville BR, Van Hecke O, Berry N, Detry MA, Saunders C, Fitzgerald M, Harris V, Djukanovic R, Gadola S, Kirkpatrick J, de Lusignan S, Ogburn E, Evans PH, Thomas NP, Patel MG, Hobbs FD. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. The Lancet. Respiratory Medicine. September 2021. doi:10.1016/S2213-2600(21)00310-6 · PMID 34329624 · PMC8315758
126. Journal / agency Sharma S, Bhatt P, Asdaq S, Alshammari M, Alanazi A, Alrasheedi N, Alrashdi B, Alyami S, Alhazmi B, Alam P, Sharma P, Tomar R, Arora M, Imran M. Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review. J Infect Public Health. May 2022. doi:10.1016/j.jiph.2022.03.014 · PMID 35462191 · PMC8964533
127. Journal / agency Ohe M. Multi-drug Treatment for COVID-19-induced Acute Respiratory Distress Syndrome. Turk J Pharm Sci. February 2022. doi:10.4274/tjps.galenos.2021.63060 · PMID 35227056 · PMC8892560
128. Journal / agency Dorobisz K, Dorobisz T, Janczak D, Zatoński T. Doxycycline in the Coronavirus Disease 2019 Therapy. Ther Clin Risk Manag. 2021. doi:10.2147/TCRM.S314923 · PMID 34584416 · PMC8464303
129. Journal / agency Saliy O, Popova M, Tarasenko H, Getalo O. Development strategy of novel drug formulations for the delivery of doxycycline in the treatment of wounds of various etiologies. Eur J Pharm Sci. April 2024. doi:10.1016/j.ejps.2023.106636 · PMID 38185273
130. Other Pfizer, Inc. v. International Rectifier Corp., 545 F. Supp. 486 (C.D. Cal. 1980)
131. Other Pfizer to Get Rachelle Units. 6 July 1983
132. Journal / agency Nationwide Shortage of Doxycycline: Resources for Providers and Recommendations for Patient Care. 12 June 2013
133. Other Doxycycline Capsules and Tablets. 12 December 2014
134. Other Doxycycline Hyclate Injection. 12 November 2014
135. Other FDA reports shortage of doxycycline antibiotic. What are your options?. 4 February 2013
136. Other Frio A. Sudden increase in cost of common drug concerns many. 12 March 2013
137. Other Rosenthal E. Officials Question the Rising Costs of Generic Drugs. 7 October 2014
138. Other Palmer E. Hikma hits the jackpot with doxycycline shortage. 13 March 2014
139. Other Costco Drug Information
140. Other Doxycycline Hyclate Prices and Doxycycline Hyclate Coupons
141. Other International availability for doxycycline

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.